CEO Executive AssistantMarket access has evolved from a post-approval commercial afterthought into one of the most strategically critical functions in pharmaceutical operations. A product with compelling clinical data and a strong regulatory dossier can still fail commercially if payers deny coverage, price negotiations erode margins beyond viability, or formulary placement limits patient reach. The pharmaceutical CEO must treat market access not as a late-stage commercial problem, but as a cross-functional operational discipline that begins at the earliest stages of clinical development.
This article examines how pharma CEOs build the operational infrastructure to manage market access functions effectively: from payer strategy and evidence generation to pricing governance, reimbursement operations, and the cross-functional coordination that determines whether a drug succeeds commercially after approval.
Understanding Market Access as a CEO-Level Function
Market access encompasses everything required for a therapy to reach patients and generate revenue after regulatory approval: payer coverage decisions, formulary positioning, reimbursement rates, patient access programs, and the negotiation of managed care contracts. In markets with government-controlled pricing such as Germany, the UK, and Japan, market access functions also include health technology assessment (HTA) submissions and mandatory price negotiations with national bodies.
The CEO’s role is not to manage these negotiations personally. It is to ensure that market access considerations are integrated into the organization’s strategy from the earliest stages, that the function is adequately resourced and structured, that cross-functional coordination between market access, clinical development, medical affairs, and commercial teams is operationally effective, and that pricing and access decisions are governed through a framework that protects both business sustainability and patient access.
According to McKinsey research on pharmaceutical value realization, companies that integrate market access planning early in development capture significantly higher commercial value than those that engage payers reactively after approval. The operational implication for CEOs is clear: market access cannot be a phase 3 problem.
Building the Market Access Organizational Structure
The organizational question for market access is one of the most consequential structural decisions a pharma CEO makes. Should market access sit within commercial operations, reporting through the Chief Commercial Officer? Should it report directly to the CEO, signaling its strategic independence? Should there be a separate Chief Access Officer for large, complex portfolios?
For emerging biopharma companies bringing their first or second product to market, market access often reports to the Chief Commercial Officer. This is operationally appropriate when the commercial and access strategies are tightly integrated and when the CCO has the experience to manage HTA and payer engagement alongside launch planning.
For larger organizations with complex portfolios spanning multiple therapeutic areas, patient populations, and geographies, a dedicated Global Head of Market Access with a seat at the senior leadership table is a stronger structure. This person needs authority to influence clinical trial design, endpoint selection, health economic modeling, and evidence generation planning, not just to negotiate contracts after the data is locked.
The CEO should establish clear accountability boundaries between market access, medical affairs, and commercial functions. Payer scientific liaisons sit at the intersection of medical and market access. Patient support programs span commercial, access, and compliance. Confusion about ownership of these interfaces creates operational gaps that damage both revenue and patient outcomes.
Payer Strategy: Operational Principles
Payer strategy is not a single document produced at launch; it is an ongoing operational practice that must be updated as evidence accumulates, competitive landscapes shift, and payer priorities evolve.
Operationally, payer strategy requires a structured intelligence function. The market access team should maintain a continuously updated payer landscape database covering the major national and regional payers in each target market, their coverage policies for the relevant therapeutic area, their utilization management practices including prior authorization and step therapy requirements, their formulary decision-making timelines, and the evidence they prioritize in coverage determinations.
This intelligence base should inform clinical trial design. The CEO should ensure that at minimum one senior market access leader participates in the trial design process, specifically to advocate for endpoints, patient populations, and comparators that will be compelling to payers rather than only to regulators. Payers and HTA bodies often require different evidence than regulatory agencies: comparative effectiveness against current standard of care, patient-reported outcomes, real-world evidence of benefit duration, and health economic data demonstrating value relative to cost.
Payer advisory boards, convened regularly throughout clinical development, provide structured opportunities to test value propositions, identify evidence gaps, and understand the reimbursement criteria that will govern coverage decisions. These boards should be composed of formulary decision-makers from diverse payer types: commercial insurers, pharmacy benefit managers, Medicare and Medicaid in the US context, and HTA bodies in international markets.
Pricing Governance Operations
Pricing is among the highest-stakes decisions in pharmaceutical operations. Getting it wrong creates problems that are difficult to reverse: prices set too high trigger formulary exclusions and reputational damage; prices set too low leave significant revenue on the table and may signal lack of confidence in the therapy’s value. The CEO needs a pricing governance framework that brings the right expertise to these decisions through a structured process.
A pricing governance committee typically includes the CEO or a designated senior executive as chair, along with the Chief Commercial Officer, Chief Medical Officer, Head of Market Access, Chief Financial Officer, and General Counsel. For products with significant international exposure, regional market access leads should participate or be formally consulted.
The committee should govern several pricing decision points: the initial US list price and net price strategy at launch, the international pricing sequence and reference pricing implications, the authorized generics or patient access pricing strategy, and any significant post-launch pricing adjustments. Each decision point should have a defined evidence base: comparable product benchmarking, health economic modeling, payer willingness-to-pay research, and modeled revenue scenarios across different coverage outcomes.
Transparency is an increasingly important dimension of pharma pricing operations. Multiple US states have enacted drug pricing transparency laws requiring reporting of list price increases and justification. Investors, patient advocacy organizations, and legislators all scrutinize pricing decisions. The CEO should ensure that pricing governance documentation is thorough enough to demonstrate the value basis for pricing decisions, even if those documents are internal.
Reimbursement Operations Infrastructure
Reimbursement operations is the execution layer of market access: the systems and processes that ensure patients can actually access and be reimbursed for therapy after coverage decisions are made. This function is frequently underestimated by pharma CEOs until launch, when its inadequacy creates patient access problems that damage both commercial results and organizational reputation.
The operational components of reimbursement infrastructure include: a hub services program that provides payer benefit verification, prior authorization support, appeals management, and claims support to patients and prescribers; a specialty pharmacy network that ensures reliable product distribution and patient adherence support; a co-pay assistance program for commercially insured patients with cost-sharing obligations; and a patient assistance program for uninsured and underinsured patients who cannot access the therapy without financial support.
Each of these components requires significant operational planning, vendor selection, system integration, and staff training before launch. The CEO should ensure that market access operations planning begins at least 24 months before anticipated approval, with defined milestones and accountability owners for each operational component.
Post-launch reimbursement operations require ongoing management. Prior authorization denial rates, average time to treatment initiation, patient program enrollment rates, and specialty pharmacy dispense rates are all operational metrics that the CEO should review monthly in the first year post-launch, as they directly predict revenue realization and patient outcomes.
HTA and International Market Access Operations
For pharma companies with global ambitions, international market access adds layers of operational complexity. HTA processes in Germany (AMNOG), England and Wales (NICE), France (HAS), and Japan (PMDA) each have distinct procedural requirements, evidence standards, and negotiation processes. Managing these processes effectively requires both local expertise and global coordination.
The CEO should ensure that international market access planning is integrated into the global development program from phase 2 onward. The sequencing of international approvals and HTA submissions requires strategic decisions: Should Germany or England lead the European HTA sequence, given that German outcomes influence international reference pricing? Should Japan be pursued in the primary launch wave or in a subsequent phase?
International reference pricing is an operational risk that demands CEO-level attention. The price accepted in one country creates a floor or ceiling for negotiations in other countries that use reference pricing systems. A pricing decision made under competitive pressure in a single market can systematically erode revenue across an entire international portfolio. The CEO should ensure that the pricing governance framework explicitly incorporates international reference pricing modeling before any national price is agreed.
For additional frameworks on managing the full scope of pharmaceutical operations, our pharma operations resource provides a structured overview of the key operational priorities at each stage of organizational growth.
Cross-Functional Coordination for Market Access
Market access outcomes are determined by inputs from across the organization: clinical data generated by R&D, health economic models built by HEOR, medical evidence disseminated by medical affairs, commercial execution managed by sales and marketing, and compliance frameworks established by legal and regulatory affairs. The CEO must build the cross-functional coordination mechanisms that allow these functions to work together cohesively rather than in sequential handoffs.
The most effective operational mechanism is an integrated evidence and access team (IEAT) or equivalent cross-functional governance body that convenes representatives from all relevant functions to align on evidence generation plans, value messaging, and launch readiness across markets. This team should be established during clinical development, not at pre-launch, and should have both tactical meeting rhythms (monthly) and strategic reviews at key development milestones.
The CEO should establish clear decision rights within this cross-functional body. Who has authority to commit resources for additional evidence generation? Who can approve health economic modeling assumptions? Who signs off on value dossiers submitted to HTA bodies? Ambiguous decision rights create delays and inconsistency that compromise market access outcomes.
Patient Access and Affordability Operations
Pharmaceutical CEOs increasingly face pressure to demonstrate that their pricing and access strategies are consistent with patient access obligations, particularly for therapies addressing serious unmet medical needs. Beyond the ethical dimensions, patient access programs are operationally important because they directly influence the prescribing behavior of physicians who observe whether their patients can actually afford and obtain therapy.
A comprehensive patient access strategy includes the financial assistance programs described in the reimbursement operations section, but also encompasses patient education and support programs, disease state awareness initiatives, and engagement with patient advocacy organizations that influence payer policy and formulary decisions.
Patient advocacy engagement is an operationally complex area that requires coordination between medical affairs, market access, and communications functions, and that must be governed by transparency standards and legal compliance frameworks. The CEO should ensure there are clear policies governing the nature and documentation of patient advocacy organization interactions.
Measuring Market Access Performance
The CEO needs a market access performance dashboard that tracks leading and lagging indicators of commercial success. Leading indicators include payer coverage rates by formulary tier, prior authorization approval rates, days to treatment initiation from prescription, and specialty pharmacy dispense rates. Lagging indicators include net revenue realization as a percentage of gross-to-net assumptions, market share within covered lives, and patient persistence rates.
These metrics should be reviewed monthly by the market access leadership team and quarterly by the CEO and full commercial leadership. Deviations from plan should trigger structured root cause analysis and corrective action planning, not just narrative explanation.
Our pharma ops guide offers a comprehensive framework for integrating market access metrics into the broader pharmaceutical operational management system.
Conclusion
Market access is the operational bridge between clinical value and commercial success. Pharma CEOs who build rigorous market access systems, integrate access planning into development strategy, govern pricing decisions through structured frameworks, and build the reimbursement infrastructure that enables patient access consistently outperform those who treat access as a late-stage problem. In an era of increasing payer scrutiny, HTA complexity, and public pressure on drug pricing, operational excellence in market access is not a commercial advantage. It is a commercial necessity.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.